Progestogens in luteal support
review
OA: closed
CC0
⤵ 2 in-corpus citations
AI-generated summary
This review examines the effects of various progestogens on implantation and pregnancy rates in assisted reproduction, addressing luteal insufficiency and their use in miscarriage.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Progestational agents are often prescribed to increase the clinical pregnancy rate in assisted reproduction. Progestogens affect implantation, cytokine balance, natural killer cell activity, arachidonic acid release and myometrial contractility. Progesterone production from the corpus luteum is essential for reproduction, but assisted reproductive technologies (ART) can impair luteal function. ART cycles can be classified into three, fresh cycles in which there may or may not be luteal insufficiency, agonist or antagonist cycles in which there is luteal insufficiency, and luteal support is essential, and donor cycles, in which there is no corpus luteum, and a luteal phase has to be created. However, there is no adequate diagnostic test for luteal insufficiency. This article summarises the effect of various progestogens, progesterone itself whether administered vaginally, intra-muscularly, rectally or subcutaneously, and the effect of the progestogen, dydrogesterone. The time of commencement and cessation of therapy are also discussed. Progestogens are also often used to treat threatened and recurrent miscarriage. In these patients progestogen supplementation may need to be prolonged. In threatened miscarriage, until after all bleeding stops, and in recurrent miscarriage, at least as long as the luteo-placental shift.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
- Luteal phase support for assisted reproduction cycles 2015
- A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest® when used for luteal phase support in ICSI treatment 2012
Cited by (2)
References (37)
- A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest® when used for luteal phase support in ICSI treatment via openalex
- Luteal phase support for assisted reproduction cycles via openalex
- W1787787700 via openalex
- W1795435863 via openalex
- W1970180069 via openalex
- W1984226636 via openalex
- W2013734819 via openalex
- W2027229987 via openalex
- W2030555662 via openalex
- W2034652444 via openalex
- W2037661427 via openalex
- W2058932581 via openalex
- W2074781328 via openalex
- W2077656232 via openalex
- W2079580606 via openalex
- W2100169728 via openalex
- W2101329303 via openalex
- W2103966730 via openalex
- W2104687197 via openalex
- W2113503442 via openalex
- W2150100936 via openalex
- W2153214140 via openalex
- W2155007716 via openalex
- W2236902456 via openalex
- W2330902531 via openalex
- W2550177873 via openalex
- W2568105521 via openalex
- W2577023606 via openalex
- W2592864957 via openalex
- W2609033290 via openalex
- W2769424316 via openalex
- W2896463158 via openalex
- W2944460039 via openalex
- W4242030375 via openalex
- W48064796 via openalex
- W4244568439 via openalex
- W1632344522 via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK